4.5 Article

Sodium butyrate, an epigenetic interventional strategy, attenuates a stress-induced alteration of MK-801's pharmacologic action

期刊

EUROPEAN NEUROPSYCHOPHARMACOLOGY
卷 18, 期 8, 页码 565-568

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.euroneuro.2007.11.004

关键词

sodium butyrate; stress; NMDA receptor; MK-801; seizures

向作者/读者索取更多资源

Twenty-four hours after mice are exposed to a single session of forced swimming in cold water, the ability of MK-801 (dizocilpine), a noncompetitive NMDA receptor antagonist, to antagonize electrically precipitated seizures is reduced. Conceivably, this reduction in MK-801's antiseizure efficacy reflects a stress-induced alteration in NMDA receptor-mediated neurotransmission due to changes in gene expression 24 h after a single stress. Recently, epigenetic interventional strategies impacting expression of genes whose regulation is controlled by the acetylation status of histone proteins in the nucleosome, an octomeric complex of histone proteins and promoter regions of double-stranded DNA, have been tested in preclinical models of various neuropsychiatric disorders, including Huntington disease and major depression. These strategies have been studied extensively in cancer biology. In the current investigation, the severity of the stress-induced reduction of MK-801's ability to raise the threshold voltage for the elicitation of tonic hindlimb extension was reduced when sodium butyrate (1.5 g/kg, ip) was administered around the time of stress. Prior research showed that this dose of sodium butyrate reliably increased the acetylation status of H3 and H4 histone proteins in the hippocampus and cerebral cortex of mice. Thus, the attenuation of the stress-induced reduction of MK-801's antiseizure efficacy may be due to the increased acetylation of histone proteins in the nucleosomal core and promotion of gene expression. These data encourage development of epigenetic strategies to prevent some of the deleterious consequences of stress. Published by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Pharmacology & Pharmacy

The α7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome

Stephen I. Deutsch, Jessica A. Burket, Maria R. Urbano, Andrew D. Benson

BIOCHEMICAL PHARMACOLOGY (2015)

Article Clinical Neurology

NMDA receptor activation regulates sociability by its effect on mTOR signaling activity

Jessica A. Burket, Andrew D. Benson, Amy H. Tang, Stephen I. Deutsch

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2015)

Article Neurosciences

Characterization of gait and olfactory behaviors in the Balb/c mouse model of autism spectrum disorders

Jessica A. Burket, Chelsea M. Young, Torrian L. Green, Andrew D. Benson, Stephen I. Deutsch

BRAIN RESEARCH BULLETIN (2016)

Article Neurosciences

Age-dependent effects on social interaction of NMDA GluN2A receptor subtype-selective antagonism

Torrian L. Green, Jessica A. Burket, Stephen I. Deutsch

BRAIN RESEARCH BULLETIN (2016)

Article Clinical Neurology

The 15q13.3 deletion syndrome: Deficient α7-containing nicotinic acetylcholine receptor-mediated neurotransmission in the pathogenesis of neurodevelopmental disorders

Stephen I. Deutsch, Jessica A. Burket, Andrew D. Benson, Maria R. Urbano

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)

Article Multidisciplinary Sciences

Experimental Assessment of Mouse Sociability Using an Automated Image Processing Approach

Frency Varghese, Jessica A. Burket, Andrew D. Benson, Stephen I. Deutsch, Christian W. Zemlin

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2016)

Review Clinical Neurology

Metabotropic functions of the NMDA receptor and an evolving rationale for exploring NR2A-selective positive allosteric modulators for the treatment of autism spectrum disorder

Jessica A. Burket, Stephen I. Deutsch

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2019)

Editorial Material Clinical Neurology

Collaborative interdisciplinary approaches for a heterogeneous group of neurodevelopmental disorders; A Way forward!

Stephen I. Deutsch, Jessica A. Burket, Maria R. Urbano

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2019)

Article Clinical Neurology

Glycine transporter type 1 (GlyT1) inhibition improves conspecific-provoked immobility in BALB/c mice: Analysis of corticosterone response and glucocorticoid gene expression in cortex and hippocampus

Jessica A. Burket, Jerrah C. Pickle, Allison M. Rusk, Bronson A. Haynes, Julia A. Sharp, Stephen Deutsch

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2020)

Review Clinical Neurology

Psychotropic medication use for adults and older adults with intellectual disability; selective review, recommendations and future directions

Stephen Deutsch, Jessica A. Burket

Summary: There is a growing expert consensus on prescribing and monitoring psychotropic medications for adults and older adults with intellectual disability (ID). However, there is limited empirical evidence to guide physicians in selecting specific categories of psychotropic medications for challenging behaviors. Challenges in applying diagnostic criteria and assigning psychiatric diagnoses to adults with ID lead to confusion surrounding medication selection. Long-term antipsychotic medication use is common for challenging behaviors, despite questionable efficacy, with some recommending short-term use for imminent dangerousness or threat to residential placements. Interdisciplinary treatment teams are essential for non-pharmacological plans and regular medication monitoring. Well-designed clinical trials are necessary for homogeneous samples, with a focus on safety and clinical outcomes. Innovative pharmacological strategies have been suggested to prevent adaptive function decline and improve cognition in adults with ID. Translational clinical trials addressing pathogenic mechanisms and challenging behaviors raise societal issues regarding protection of vulnerable populations and prioritization of therapeutic targets.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2021)

Review Biochemistry & Molecular Biology

Targeted NMDA Receptor Interventions for Autism: Developmentally Determined Expression of GluN2B and GluN2A-Containing Receptors and Balanced Allosteric Modulatory Approaches

Stephen Deutsch, Zachary N. M. Luyo, Jessica A. Burket

Summary: Various ASD risk alleles can lead to impairment of NMDA receptor activation, highlighting the need for the development of specific and selective translational therapeutic NMDA receptor agonists to restore balance.

BIOMOLECULES (2022)

Article Medicine, General & Internal

From Mouse to Man: N - Methyl-D-Aspartic Acid Receptor Activation as a Promising Pharmacotherapeutic Strategy for Autism Spectrum Disorders

Stephen I. Deutsch, Jessica A. Burket

MEDICAL CLINICS OF NORTH AMERICA (2023)

Article Biology

Exposure to Low (≤10 cGy) Doses of 4He Particles Leads to Increased Social Withdrawal and Loss of Executive Function Performance

Jessica A. Burket, Mona Matar, Arriyam Fesshaye, Jerrah C. Pickle, Richard A. Britten

Summary: Exposure to He particles can impact cognitive flexibility and social interaction in male rats, leading to deficits in executive functions and possibly affective behavior. These findings suggest that a single behavioral end point may not fully represent the cognitive deficits induced by space radiation.

RADIATION RESEARCH (2021)

Review Clinical Neurology

Sugarcoated Perineuronal Nets Regulate GABAergic Transmission: Bittersweet Hypothesis in Autism Spectrum Disorder

Jessica A. Burket, Maria R. Urbano, Stephen I. Deutsch

CLINICAL NEUROPHARMACOLOGY (2017)

Review Clinical Neurology

NMDA agonists for autism spectrum disorders: progress and possibilities

Stephen I. Deutsch, Jessica A. Burket, Andrew D. Benson, Maria R. Urbano

FUTURE NEUROLOGY (2015)

Article Clinical Neurology

A posterior-alpha ageing network is differentially associated with antidepressant effects of venlafaxine and rTMS

Hannah Meijs, Helena Voetterl, Alexander T. Sack, Hanneke van Dijk, Bieke De Wilde, Jan Van Hecke, Peter Niemegeers, Evian Gordon, Jurjen J. Luykx, Martijn Arns

Summary: This study used a polygenic score (PGS) and electroencephalography (EEG) data analysis to identify potential predictors for treatment outcomes in major depressive disorder (MDD). The results suggest the existence of a stable EEG network related to antidepressant-response that has potential as a predictor for MDD treatment, particularly in the case of venlafaxine.

EUROPEAN NEUROPSYCHOPHARMACOLOGY (2024)